Patients with breast cancer receiving antiestrogen therapy, specifically aromatase inhibitors,
often suffer from vaginal dryness, itching, irritation, dyspareunia, and dysuria, collectively …

Importance Geriatric (aged≥ 80 years) patients are historically underrepresented in cancer
clinical trials. Little is known about the efficacy of immune checkpoint inhibitors (ICIs) in …

Background Thromboembolism (TE) in cancer significantly contributes to morbidity and
mortality. Little is known about the incidence of arterial TE (ATE) and venous TE (VTE) in …

Background: Uveal melanoma is a rare subtype of melanoma. Prognosis and survival rates
for patients with metastatic uveal melanoma remain poor. No current FDA-approved …

Background Over one third of American adults are at high risk for developing diabetes,
which can be delayed or prevented using interventions such as medical nutrition therapy …

Background Metastatic renal cell carcinoma (mRCC) is associated with a high risk of
thromboembolism (TE). Objective We investigated whether immunotherapy (IO) increases …

Background Immunotherapy has become one of the mainstays for metastatic urothelial
carcinoma treatment. Whether immune checkpoint inhibitor therapy increases …

Background The propensity to develop venous thromboembolism (VTE) on the basis of
individual tumor biological features remains unknown. Objectives We conducted a whole …

To evaluate factors affecting the utilization of immunotherapy and to stratify results based on
the approval of ipilimumab in 2011 and PD-1 inhibitors in 2014, an analysis of available …

Background To evaluate factors affecting the utilization of immunotherapy and to stratify
results based on the approval of ipilimumab in 2011 and programmed death-1 inhibitors in …